Distribution of Bexsero® Antigen Sequence Types (BASTs) in invasive meningococcal disease isolates: Implications for immunisation

Brehony, C., Rodrigues, C. M.C., Borrow, R., Smith, A. , Cunney, R., Moxon, E. R. and Maiden, M. C.J. (2016) Distribution of Bexsero® Antigen Sequence Types (BASTs) in invasive meningococcal disease isolates: Implications for immunisation. Vaccine, 34(39), pp. 4690-4697. (doi: 10.1016/j.vaccine.2016.08.015) (PMID:27521232) (PMCID:PMC5012890)

122473.pdf - Published Version
Available under License Creative Commons Attribution.



Serogroup B is the only major disease-associated capsular group of Neisseria meningitidis for which no protein-polysaccharide conjugate vaccine is available. This has led to the development of multi-component protein-based vaccines that target serogroup B invasive meningococcal disease (IMD), including Bexsero®, which was implemented for UK infants in 2015, and Trumenba®. Given the diversity of meningococcal protein antigens, post-implementation surveillance of IMD isolates, including characterisation of vaccine antigens, is essential for assessing the effectiveness of such vaccines. Whole genome sequencing (WGS), as realised in the Meningitis Research Foundation Meningococcus Genome Library (MRF-MGL), provides a rapid, comprehensive, and cost-effective approach to this. To facilitate the surveillance of the antigen targets included in Bexsero® (fHbp, PorA, NHBA and NadA) for protective immunity, a Bexsero® Antigen Sequence Type (BAST) scheme, based on deduced peptide sequence variants, was implemented in the PubMLST.org/neisseria database, which includes the MRF-MGL and other isolate collections. This scheme enabled the characterisation of vaccine antigen variants and here the invasive meningococci isolated in Great Britain and Ireland in the epidemiological years 2010/11 to 2013/14 are analysed. Many unique BASTs (647) were present, but nine of these accounted for 39% (775/1966) of isolates, with some temporal and geographic differences in BAST distribution. BASTs were strongly associated with other characteristics, such as serogroup and clonal complex (cc), and a significant increase in BAST-2 was associated with increased prevalence of serogroup W clonal complex 11 meningococci. Potential coverage was assessed by the examination of the antigen peptide sequences present in the vaccine and epidemiological dataset. There were 22.8–30.8% exact peptide matches to Bexsero® components and predicted coverage of 66.1%, based on genotype-phenotype modelling for 63.7% of serogroup B isolates from 2010/14 in UK and Ireland. While there are many caveats to this estimate, it lies within the range of other published estimates.

Item Type:Articles
Additional Information:The work was supported by Meningitis Research Foundation. We made use of the Meningitis Research Foundation Meningococcus Genome Library developed by Public Health England, the Wellcome Trust Sanger Institute, and the University of Oxford. The Meningitis Research Foundation Meningococcus Genome Library is part of the Neisseria Sequence Typing database website developed by Keith Jolley and Martin Maiden and hosted by the University of Oxford and supported by the Wellcome Trust (Grant 104992). CMCR was supported by Wellcome Trust (Grant 109031/Z15/Z). MCJM had been supported by the Wellcome Trust (Grant 087622).
Glasgow Author(s) Enlighten ID:Smith, Professor Andrew
Authors: Brehony, C., Rodrigues, C. M.C., Borrow, R., Smith, A., Cunney, R., Moxon, E. R., and Maiden, M. C.J.
College/School:College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing > Dental School
Journal Name:Vaccine
ISSN (Online):1873-2518
Published Online:09 August 2016
Copyright Holders:Copyright © 2016 The Authors
First Published:First published in Vaccine 34(39):4690-4697
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record